Japanese encephalitis vaccine, inactivated, adsorbed - Biologic Drug Details

Summary for japanese encephalitis vaccine, inactivated, adsorbed

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for japanese encephalitis vaccine, inactivated, adsorbed

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Japanese Encephalitis Virus Vaccine
Chemical Structure	Japanese Encephalitis Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for japanese encephalitis vaccine, inactivated, adsorbed Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for japanese encephalitis vaccine, inactivated, adsorbed Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Valneva Austria Gmbh	IXIARO	japanese encephalitis vaccine, inactivated, adsorbed	Injection	125280		2018-08-25	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for japanese encephalitis vaccine, inactivated, adsorbed Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Market Dynamics and Financial Trajectory for the Inactivated, Adsorbed Japanese Encephalitis Vaccine

Last updated: August 1, 2025

---

Introduction

Japanese Encephalitis (JE), caused by the Japanese Encephalitis Virus (JEV), remains a significant public health concern across Asia-Pacific regions. The inactivated, adsorbed JE vaccine has long been a cornerstone of preventative strategies, with its market dynamics shaped by epidemiological trends, technological advancements, policy frameworks, and competitive landscape. This article explores the key drivers impacting the market and forecasts the financial trajectory of this critical vaccine.

---

Epidemiological and Public Health Drivers

The global burden of JE extends across 24 countries, with an estimated 68,000 cases annually, predominantly in Southeast Asia and the Western Pacific [1]. The disease's severity, high case-fatality rate (20-30%), and the risk of long-term neurological deficits underscore the demand for effective vaccination programs.

Government-led immunization initiatives constitute primary market drivers. Countries like India, China, and South Korea have integrated JE vaccination into routine immunization schedules, bolstered by WHO recommendations [2]. These policies significantly influence vaccine uptake rates and, consequently, market expansion. However, sporadic outbreaks in non-endemic regions raise ongoing demands for stockpiling and reactive immunization.

Climate change alters vectors' habitats, potentially expanding JE endemic zones, thereby increasing future demand. Conversely, variations in vector populations and environmental factors could temporarily impede transmission, muting short-term market growth.

---

Technological and Product Innovations

The traditional inactivated, adsorbed JE vaccine, produced via formalin-inactivation of JEV and absorbed onto aluminum hydroxide, boasts a well-established efficacy profile validated over decades. However, newer formulations, including live-attenuated and recombinant vaccines, are entering the market, challenging traditional options through superior immunogenicity and fewer doses.

Despite these innovations, the inactivated, adsorbed vaccine retains its dominance due to its proven safety and stability profiles, especially in pediatric populations. Furthermore, manufacturing scale-up and global regulatory acceptance favor its continued prevalence.

Recent advancements aim to improve thermostability, reducing cold chain dependence, thereby expanding access in resource-limited settings—a pivotal factor in rural Asia.

---

Regulatory and Market Access Dynamics

Regulatory approvals in key markets, driven by agencies such as the WHO, FDA, and EMA, promote market confidence. WHO prequalification facilitates procurement by UNICEF and GAVI, crucial for low-income countries’ immunization programs.

Market access is further influenced by cost considerations. The inactivated vaccine's manufacturing complexity results in higher production costs compared to live-attenuated alternatives. Nevertheless, bulk purchasing agreements and subsidies have mitigated affordability barriers.

Trade policies, intellectual property rights, and local manufacturing capabilities significantly shape the competitive landscape. For instance, India’s Serum Institute and China’s CNBG produce inactivated JE vaccines locally, intensifying regional competition and affecting global pricing strategies.

---

Competitive Landscape and Market Players

Leadership is primarily held by entities like Sanofi Pasteur (India), Chengdu Institute of Biological Products (China), and Indian immunization programs utilizing locally manufactured vaccines. Market entry barriers include stringent regulatory requirements and complex manufacturing processes.

The proliferation of regional manufacturers has driven down prices, fostering greater access but intensifying market competition. Strategic alliances and licensing agreements further influence the competitive dynamics.

Emerging biotechnology firms exploring recombinant and mRNA platforms pose potential disruptions but remain in early development phases as of 2023.

---

Market Size and Financial Trajectory

Pre-pandemic estimates pegged the global JE vaccine market size at approximately USD 180 million in 2019, with projections growing at a CAGR of around 7% through 2027 [3].

The increasing integration of JE vaccination into national immunization programs, especially in endemic and at-risk areas, is expected to sustain steady growth. The expansion of vaccination coverage and introduction of combined vaccines (e.g., JE with other pediatric antigens) contribute positively.

The COVID-19 pandemic initially disrupted supply chains and immunization schedules; however, recovery phases demonstrate a resilient market fueled by continued demand and health system strengthening initiatives.

Forecasting the financial trajectory indicates sustained growth driven by:

• Expanding endemic zones due to climate shifts.
• Government investments in immunization infrastructure.
• Affordable manufacturing by regional players.

Notably, high-income markets like Japan and Australia exhibit stable, mature markets with moderate growth, whereas low- to middle-income countries present higher growth potential owing to vaccination program expansions.

---

Strategic Opportunities and Challenges

Opportunities:

• Development of thermostable formulations to improve cold chain logistics.
• Integration into combination vaccines to streamline immunization schedules.
• Leveraging regional manufacturing to reduce prices and optimize supply.

Challenges:

• Competition from newer vaccine platforms with superior immunogenicity.
• Regulatory challenges, especially with complex biologics.
• Vaccine hesitancy resulting from safety concerns or misinformation.

Addressing these challenges requires continuous innovation, strategic partnerships, and robust public health campaigns.

---

Key Takeaways

• Epidemiology remains the primary driver for vaccine demand, with high impact in endemic regions and emerging zones impacted by climate change.
• Technological advancements favor the inactivated, adsorbed vaccine’s longevity but pressure from innovative platforms persists.
• Market access and pricing strategies are pivotal, influenced by local manufacturing and international procurement programs.
• Market size is projected to grow at a CAGR of approximately 7%, driven by expanding immunization efforts and regional manufacturing capacity.
• Competition and innovation will redefine the landscape, emphasizing the importance of maintaining vaccine efficacy, safety, and affordability.

---

FAQs

1. What are the main factors influencing the demand for inactivated JE vaccines?
   The demand is chiefly driven by endemic disease prevalence, government immunization policies, public health priorities, and environmental factors that affect JEV transmission.

2. How does climate change impact the market for JE vaccines?
   Climate change alters mosquito habitats, potentially expanding JE-endemic regions and increasing future vaccine demand in new zones.

3. Who are the leading manufacturers of the inactivated, adsorbed JE vaccine?
   Major players include Sanofi Pasteur (India), Chengdu Institute of Biological Products (China), and regional government-led manufacturing facilities.

4. What are the technological trends shaping the future of JE vaccination?
   Innovations focus on thermostable formulations, combination vaccines, and exploring recombinant or mRNA-based platforms to enhance efficacy and logistics.

5. What are the primary challenges facing the JE vaccine market?
   Challenges include the emergence of competing vaccine platforms, regulatory hurdles, vaccine hesitancy, and high manufacturing costs impacting affordability.

---

References

[1] World Health Organization. "Japanese Encephalitis". 2022.
[2] WHO. "Japanese Encephalitis Vaccines: WHO Position Paper". 2013.
[3] Market Research Future. "Japanese Encephalitis Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020–2027". 2020.